

## SPINRAZA PRIOR AUTHORIZATION FORM

Incomplete forms will be returned 1-800-492-5231-Option 3 Fax form to 410-333-5398

## <u>Please attach copies of the patient's medical history summary, lab and genetic test reports to the State.</u> \*\*Please review our clinical criteria before submitting this form. \*\*

| Patient Information:   |   |
|--|---|
| NAME:  | DOB:  |
| Recipient's Maryland Medicaid Number:  | SEX: □ M □ F  |
| Prescriber Information:  | Name of Facility/Clinic:  |
| <del></del>  |   |
| NAME:  | NPI #   |
| Phone #  | Fax #   |
| Contact Person for this Request:   |   |
| NAME: Phone #  | Fax #   |
| Billing: (Choose one)  □ Dispensed and billed by the Pharmacy Pro □ Furnished and billed directly by the Presco Has patient received previous treatment with  If yes, what was the start date?  Is patient enrolled in a clinical trial? Yes | Spinraza? Yes No and how many doses has patient received?   |
| Maryland Medicaid considers Spinraza™ Atrophy (SMA) in patients when ALL of th □ Diagnosis of SMA Type I, II or III; □ Diagnosis by a neurologist with expe  |   |
| mutation; AND  ☐ At least 2 copies of SMN2  AND  ☐ Patient is not dependent on invasive  | n, homozygous gene mutation, or compound heterozygous e ventilation or tracheostomy; asive ventilation beyond use for naps and nighttime sleep; |

## **AND**

| Spinraza<br>Spinraza<br>experien   | ta has been prescribed by a neurologist expect will be given according to the current FD to a will be administered intrathecally by a phonced in performing lumbar punctures ial Therapy   | A labelling guidelines for dosage and timing;  |
|--|--|--|
| <ul><li>Medical</li><li>Medical</li><li>followin</li><li>H</li><li>H</li></ul> | I records must be submitted documenting a  | a baseline motor examination utilizing at least one of the r ability) to establish baseline motor ability: INE)  |
|  | Upper Limb Module Test (non-ambulatory)<br>Children's Hospital of Philadelphia Infant Te   | est of Neuromuscular Disorders (CHOP-INTEND)   |
| Note: Initi  | tially, Spinraza will be preauthorized for 4 le  | pading doses when criteria are met.  |
| For Con  | ntinuing Therapy   |  |
| <ul><li>All of the</li><li>Medical<br/>(and not</li></ul>                      | pinraza maintenance dose must be preautl<br>ne criteria for initial therapy must be met;<br>I records must be submitted that document<br>of more than 1 month prior to the next sche-<br>e motor ability, unless it is determined that | repeat motor testing since the most recent Spinraza dose duled dose) using the same motor test done to establish |
| Repeat m  1. HINE  | notor testing must document a response to  | treatment as defined by the following:   |
|  | Improvement or maintenance of previous of 4) in ability to kick (improvement in at   | s improvement of at least 2 points (or max score least 2 milestones);  |
|  | motor milestones of head control, rolling improvement by at least 1 milestone);  | s improvement of at least 1 point increase in sitting, crawling, standing or walking (consistent with            |
|  | <ul><li>AND</li><li>Improvement or maintenance of previous worsening;</li></ul>  | s improvement in more HINE motor milestones than   |
| 2. HFMS  | SE   |  |
| 3. ULM   | ·  | ment of at least a 3 point increase in score;  |
| 4. CHOP  | <ul> <li>Improvement or maintenance or previous</li> <li>P-INTEND</li> </ul>   | s improvement of at least 2 point increase in score;   |
|  |  | s improvement of at least 4 point increase in score.   |
|  | hat benefit of treatment for this patient outvice is true and accurate to the best of my know  | veigh the risks and verify that the information provided on vledge.  |
| Prescriber   | er's Signature   | Date   |

Fax completed form to 410-333-5398